clinical trial · NCT03614949
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
H. Lee Moffitt Cancer Center and Research Institute·phase2·active not recruiting·n = 21
Cervical CancerCervical Cancer RecurrentCervical Cancer MetastaticStereotactic body radiation therapy (SBRT)Atezolizumab
brief summary
The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy (SBRT) will improve the objective response rate (ORR) compared with atezolizumab alone in patients with recurrent, persistent, or metastatic cervical cancer.
started
Jan 29, 2019
primary completion
Oct 1, 2028
completion
Oct 1, 2028
last updated
Apr 1, 2026
official title
Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol